Phase II study of methyl-CCNU, vincristine, 5-fluorouracil, and streptozotocin in advanced colorectal cancer. By the Gastrointestinal Tumor Study Group.
In an attempt to confirm the previously reported response rates with methyl-CCNU, vincristine, 5-fluorouracil, and streptozotocin (MOF-strep) (34%) in advanced colorectal cancer, the Gastrointestinal Tumor Study Group used the identical treatment schedule in 40 good performance status patients who had received no prior chemotherapy. Four patients (10%) achieved an objective partial tumor response and the median survival for all patients was 7.3 months. The toxicity was evidenced by moderate nausea and vomiting and myelosuppression with one treatment-related death. Based on this trial further evaluation of MOF-strep for advanced colorectal cancer cannot be recommended.